7.2 Relaxin-3 and the behavioral dimension of metabolic disease Relaxin-3, a member of the relaxin peptide family predominantly expressed in the nucleus incertus, signals through the RXFP3 receptor and exerts pronounced effects on feeding behavior, arousal, stress responsiveness, and cognitive processing in animal models (Smith et al., 2014)
Furthermore, ammonia-lowering therapy is a potential treatment not only for HE, but also for sarcopenia, with benefits for both muscle mass and strength [47, 48]
Glutathione (GSH) is a tripeptide comprised of three amino acids L-cysteine, L-glutamic acid and glycine
ColonBroom includes berberine at 200 mg per serving, well below the 5001,500 mg daily dose used in clinical research
Over the past few years, incretins have been clinically validated as targets and are now the emerging standard of care therapies in obesity, but could also be effective in other metabolic indications, as well as in cardiovascular and chronic kidney disease
the child may be, for example, between ages 0-15, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 years old, or any age therebetween, or any age range spanning between such ages
